Investigating the effects of Telitacicept injections in healthy Chinese adults

An Open-label, Randomized, Parallel Group, Single Dose Study to Investigate the Pharmacokinetics of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects

This study is testing two types of Telitacicept injections to see how they work and if they are safe for healthy Chinese adults.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 248 (estimated)
• Ages: 18 Years to 50 Years
• Sex: All
• Sponsor: RemeGen Co., Ltd. (Industry-sponsored)
• Locations: 3 sites (Guiyang, Guizhou and 2 other locations)
• Trial ID: NCT06549959 on ClinicalTrials.gov

What this trial studies

This open-label, randomized, parallel group study evaluates the pharmacokinetics and safety of two forms of Telitacicept injections in healthy Chinese subjects. Participants will receive either a pre-filled injection or a freeze-dried powder injection, both at a dose of 80mg. The study aims to gather data on how the drug is processed in the body and its safety profile. It includes a thorough screening process to ensure participants meet specific health criteria.

Who should consider this trial

Good fit: Ideal candidates are healthy Chinese adults aged 18-50 with specific weight and BMI criteria.

Not a fit: Patients with a history of significant health issues or those involved in the trial's implementation will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the pharmacokinetics of Telitacicept, potentially leading to improved treatment options for conditions requiring this medication.

How similar studies have performed: While this study focuses on a specific population and drug formulation, similar pharmacokinetic studies have shown success in evaluating drug safety and efficacy.

Eligibility criteria

Inclusion Criteria:

1. 18-50 years old at the time of signing the informed consent form，gender is unlimited；
2. Male Weight 55-70 kg, female Weight 50-65 kg, and BMI ranging from 18 to 28 kg/m2 (including critical values);
3. Physical examination, vital signs, chest radiographs, ECG, epidemiologic tests, routine blood tests, blood biochemistry, lipids, urinalysis, and coagulation are normal，or abnormal by the investigator as having no clinical significance；
4. Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written informed consent, and be able to complete all trial procedures according to the trial requirements.

Exclusion Criteria:

1. Site staff and family members directly involved in the trial; or sponsor staff and family members directly involved in the implementation of the trial;
2. History of any of any nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood and lymphatic system, skeletal muscle system, immune system, metabolic system disease, or other diseases that are not suitable for clinical trials (such as mental history, malignant tumors, etc.);
3. History of lymphoproliferative disease (e.g., EB virus associated lymphoproliferative disease), lymphoma, leukemia, myeloproliferative disease, multiple myeloma, or signs and symptoms suggestive of lymphoproliferative disease;
4. History of abnormal bleeding or coagulation disorders (such as prone to bruising, gingival bleeding, prolonged bleeding after tooth extraction, joint hemorrhage, heavy menstruation leading to anemia within 1 year, postpartum hemorrhage, vitamin K deficiency, hemorrhagic disease caused by acquired coagulation factor antibodies, bleeding after trauma or surgery, etc.) , or abnormal laboratory coagulation parameters, or an inherited tendency to bleed or have coagulation dysfunction, or have a history of blood clots or bleeding, or require long-term use of anticoagulants or antiplatelet aggregation drugs;
5. During screening, 12-lead ECG showing QTcF≥450 ms in male or QTcF≥470 ms in female, or the presence of degree II/III atrioventricular block, or other clinically significant ECG abnormalities are judged by investigators not inappropriate;
6. The first-degree relatives of the subject had inherited immunodeficiency;
7. Current allergic disease, or history of allergy to therapeutic or diagnostic protein products ,allergy to alcohol(alcohol is used to sterilize injection sites), or allergy to two or more drugs and/or non-drug factors;
8. Surgery within 6 months prior to screening, or planned surgery during the trial, or within 2 weeks of the end of the trial(including cosmetic surgery, dental surgery, oral surgery, etc.);
9. Participation in a clinical trial of another drug within 3 months prior to screening;
10. Use of drugs that inhibit or induce hepatic metabolism within 4 weeks prior to randomization or need for use during the trial(e.g., inducers--barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors--SSRI antidepressants, cimetidine, Diltiazem macrolides, nitroimidazoles, sedatives and hypnotics, verapamil, fluoroquinolones, antihistamines);
11. Current use of any prescription or over-the-counter (herbal, vitamins, or healthcare products). Current use is defined as use within 14 days or PK equivalent of 5 half-lives prior to randomization, whichever is longer;
12. History of Bleeding or donated more than 100ml blood 3 months before screening period, or plan to denote blood within 1 month after the trial;
13. Positive breath test results for alcohol or alcoholism in the 6 months prior to the screening period(≥14 units of alcohol per week: one standard unit contains 14g of alcohol, equals to 360ml of beer, 45ml of 40% liquor or 150ml of wine), or unable to stop drinking during the trial;
14. More than 5 cigarettes per day within 6 months prior to screening , or unable to quit smoking during the trial;
15. Consume excessive caffeine-containing beverages, foods that may affect drug metabolism within four weeks prior to screening: coffee (≥1100 mL per day), tea (≥2200 mL per day), cola (≥2200 mL per day), energy drinks (≥1100 mL per day), chocolate (≥510 g per day);
16. History of drug abuse, drug dependence, or drug use within 5 years prior to screening；
17. Subject may use weight-loss medications, or excessive dieting, or overeating during the trial;
18. Tattoos, scarring, or other conditions in the planned injection site area (front of thigh) that may interfere with the evaluation of the injection site;
19. COVID-19 vaccine within 2 weeks prior to randomization，or live vaccine within 30 days prior to randomization， or live vaccine required during the trial;
20. Positive test for Hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, Treponema pallidum antibody, tuberculin test (IGRAs);
21. History of any clinically significant infections within 6 months prior to screening (e. g., requiring hospitalization or parenteral antimicrobial therapy or opportunistic infections);
22. History of symptomatic herpes zoster or herpes simplex, more than one episode of localized herpes zoster, or disseminated herpes zoster (single episode) within 12 weeks prior to screening；
23. Female subjects with a positive pregnancy test during screening period，or lactating female ; subjects and their partners do not agree to take effective contraceptive measures (such as intrauterine devices, contraceptives or condoms) throughout the trial and within 4 months after injection of the Investigational drug;
24. Investigators believe that there are other factors that are not suitable for participating in the experiment.

Where this trial is running

Guiyang, Guizhou and 2 other locations

• The Affiliated Hospital of Guizhou Medical University — Guiyang, Guizhou, China (Recruiting)
• West China Hospital of Sichuan University — Chengdu, Sichuan, China (Recruiting)
• Tianjin People's Hospital — Tianjin, Tianjin Municipality, China (Recruiting)

Study contacts

• Study coordinator: Binghua Xiao

Conditions Healthy